Receptor News and Research

RSS

arGEN-X advances ARGX-112 into formal preclinical development

arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.

25 Mar 2013

Study shows why certain drugs that interact with serotonin receptors have harmful effects

A team including scientists from The Scripps Research Institute (TSRI), the University of North Carolina at Chapel Hill and the Chinese Academy of Sciences has determined and analyzed the high-resolution atomic structures of two kinds of human serotonin receptor.

25 Mar 2013

Alarming report on persistent side effects of antidepressant drugs published online

An alarming report from patient online websites on persistent side effects of antidepressant drugs has been published in one of the last issue of Psychotherapy and Psychosomatics by investigators from the University of Bologna and North America.

21 Mar 2013

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy, announced today that it is developing a SARM drug candidate obtained from Belgium-based Galapagos NV.

21 Mar 2013

CPF and PFF to partner with ATS to fund pulmonary fibrosis research

The Coalition for Pulmonary Fibrosis, the Pulmonary Fibrosis Foundation, and the American Thoracic Society-the world's leading professional organization for pulmonary, critical care and sleep medicine-today announced that the CPF and the PFF will again partner with the ATS to fund pulmonary fibrosis research.

21 Mar 2013

Researchers develop promising drug candidate to treat psoriasis

Ben-Gurion University of the Negev researchers, in collaboration with Teva Pharmaceutical Industries Ltd., have developed a promising drug candidate to treat psoriasis.

21 Mar 2013

Study: Drug normally used to treat severe bronchial asthma beneficial for chronic urticaria sufferers

An international study involving dermatologists from the Hospital del Mar and Spanish subjects has concluded that a drug normally used to treat severe bronchial asthma caused by allergies (Omalizumab) rapidly eliminates the symptoms of spontaneous chronic urticaria, a development that it is expected will significantly improve the quality of life of chronic urticaria sufferers.

21 Mar 2013

Combination of HUCBCs and Simvastatin offers promising therapy for stroke: Study

Researchers at the Henry Ford Health System (Detroit, MI) and colleagues at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, have found that when human umbilical cord blood cells were transplanted into test rats modeled with stroke, the addition of Simvastatin to the HUCBCs significantly increased the therapeutic benefit of the HUCBCs.

21 Mar 2013

Antagonist drug Emend halts brain tumor growth

New research from the University of Adelaide has shown for the first time that the growth of brain tumors can be halted by a drug currently being used to help patients recover from the side effects of chemotherapy.

20 Mar 2013

St. Jude Children's Research Hospital receives patent for genetically modified human immune cells for caner therapy

The United States Patent and Trademark Office today awarded St. Jude Children's Research Hospital U.S. patent number 8,399,645 for St. Jude's invention of compositions for genetically modifying human immune cells so they can destroy some of the most common forms of cancer in children and adults.

20 Mar 2013

Research findings could lead to development of new drugs for gout treatment

Findings from a Loyola University Chicago Stritch School of Medicine study could lead to the development of new drugs to treat gout.

20 Mar 2013

Scientists open door to significantly improved treatments for multiple sclerosis

A team of basic and clinical scientists led by the University of Montreal Hospital* Research Centre's Dr. Nathalie Arbour has opened the door to significantly improved treatments for the symptoms of Multiple Sclerosis.

20 Mar 2013

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

19 Mar 2013

Cytomegalovirus employs a novel trick to hide from immune detection

A virus that most people have probably never heard of, yet most of us carry, is the number 1 infectious cause of congenital birth defects. One in 750 children are born with, or develop, permanent disabilities such as hearing loss or brain damage as a result of CMV (cytomegalovirus) infection in the womb.

17 Mar 2013

Abiraterone's anti-androgenic properties may stop tumor growth of CRPC, says prize-winning Dutch study

As part of an EU-supported IMI-PREDECT consortium, a Dutch study showed that anti-androgenic properties of the drug abiraterone may provide an additional mechanism of action in blocking tumour growth of castration resistant prostate cancer (CRPC).

16 Mar 2013

CHOP expert to receive Pediatric Oncology Award from ASCO

The American Society of Clinical Oncology today announced it will confer one of its highest awards on pediatric oncologist Garrett M. Brodeur, M.D., of the Cancer Center at The Children's Hospital of Philadelphia.

16 Mar 2013

Study: Novel strategy could lead to universal influenza vaccine that can provide long-lasting protection

Seasonal epidemics of influenza result in nearly 36,000 deaths annually in the United States, according to the Centers for Disease Control. Current vaccines against the influenza virus elicit an antibody response specific for proteins on the outside of the virus, specifically the hemagglutinin protein.

15 Mar 2013

New hunt for intrinsic mechanism linked to schizophrenia

Since the 1960s, psychiatrists have been hunting for substances made by the body that might accumulate in abnormally high levels to produce the symptoms associated with schizophrenia. In particular, there was a search for chemicals that might be related to the hallucinogens phencyclidine (PCP) or lysergic acid diethylamide (LSD), which could explain the emergence of psychotic symptoms in schizophrenia.

15 Mar 2013

Researchers identify enzymes that activate coronavirus for infection

Scientists all over the world are on a quest for an antidote since the first patient died from the new coronavirus in summer 2012. Infection Researchers from the German Primate Center have now identified enzymes that activate the virus for infection.

15 Mar 2013

Results from GTx's Phase 2 clinical trial of enobosarm published online

GTx, Inc. today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition the results from GTx's randomized, double-blind, placebo-controlled Phase 2 clinical trial of enobosarm to assess its effects on muscle wasting and physical function in patients with cancer.

15 Mar 2013

Receptor News and Research

arGEN-X advances ARGX-112 into formal preclinical development

Study shows why certain drugs that interact with serotonin receptors have harmful effects

Alarming report on persistent side effects of antidepressant drugs published online

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

CPF and PFF to partner with ATS to fund pulmonary fibrosis research

Researchers develop promising drug candidate to treat psoriasis

Study: Drug normally used to treat severe bronchial asthma beneficial for chronic urticaria sufferers

Combination of HUCBCs and Simvastatin offers promising therapy for stroke: Study

Antagonist drug Emend halts brain tumor growth

St. Jude Children's Research Hospital receives patent for genetically modified human immune cells for caner therapy

Research findings could lead to development of new drugs for gout treatment

Scientists open door to significantly improved treatments for multiple sclerosis

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Cytomegalovirus employs a novel trick to hide from immune detection

Abiraterone's anti-androgenic properties may stop tumor growth of CRPC, says prize-winning Dutch study

CHOP expert to receive Pediatric Oncology Award from ASCO

Study: Novel strategy could lead to universal influenza vaccine that can provide long-lasting protection

New hunt for intrinsic mechanism linked to schizophrenia

Researchers identify enzymes that activate coronavirus for infection

Results from GTx's Phase 2 clinical trial of enobosarm published online

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News